Remdesivir Potentially Most Effective For Coronavirus: China Investigator
Executive Summary
Although AbbVie’s Kaletra has shown promising efficacy in COVID-19 patients, Gilead’s remdesivir has stronger antiviral activity, says one Chinese investigator leading studies in the coronavirus outbreak epicenter Wuhan.
You may also be interested in...
Gilead’s Major Challenge Is Sustainable Model For Remdesivir
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
Gilead's Remdesivir Results Encouraging, Safety Brings Skepticism
Analysts see NIAID’s placebo-controlled data as more important than Gilead’s open-label data. Quick emergency use authorization by FDA is possible, but the US agency has not confirmed EUA.
China Lays Out Requirements For Biosimilar Extrapolation
In what could be a blow to some aspiring developers eyeing the nascent but growing biosimilars market in China, new rules lay out when extrapolation of approved indications of reference biologics will be allowed, meaning this will not be automatic.
Need a specific report? 1000+ reports available
Buy Reports